NASTOYaShchEE I BUDUShchEE TARGETNOY TERAPII V PERVOY LINII LEChENIYa RAKA YaIChNIKOV
- Authors: Tyulyandina A.S1
-
Affiliations:
- Issue: No 8 (2013)
- Pages: 39-42
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/281138
- ID: 281138
Cite item
Open Access
Access granted
Abstract
Chemotherapy for advanced ovarian cancer remains a challenge. Despite the high rate of complete remissions after maximum cyto-reduction and first-line chemotherapy, most patients experience the relapse of disease. In the last 15 years, the combination with the addition of platinum-based drugs and taxanes remains the scheme of choice. The individualization of treatment, including the determination of the optimal combination with one of the studied targeted agents for each patient, is a promising direction for the increasing the effectiveness of first-line chemotherapy. To date, the most studied group of drugs is anti-angiogenic drugs, the positive results came from studies of bevacizumab in first-line chemotherapy. This article reviews modern treatment regimens studied within the framework of the first-line treatment of ovarian cancer with the use of promising new targeted agents.
Keywords
Full Text
References
- Gore M., Harrias M. Chemotherapy for epithelial ovarian cancer - treatment at first diagnosis. The Lancet Oncology 2002;3:529-36.
- Chung A.S., Lee J., Ferrara N., et al. Targeting the tumor vasculare: insight from the physiological angiogenesis. Nat Rev Cancer 2010;1 0:505-14.
- Nagy J.A., Dvorak A.M., Dvorak H.F. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2007;2:251-75.
- Burger R.A., Brady M.F., Bookman M.A., et al. Incorporation of Bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-83.
- Perren T.J., Swart A.M., Pfisterer J., et al. A phase 3 trial of Bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484-96.
- Bamberger E.S., Perrett C.W. Angiogenesis in epithelian ovarian cancer. Mol Pathol 2002;55 (6):348-59.
- Auersperg N., Maines-Bandiera S.L., Dyck H.G., et al. Characterization of cultured human ovarian surface epithelial cells: phenotypic plas inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012;30(4):372-79.
- Lederman J., Harter P., Gourley C., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382-92.
- Kalli K.R., Oberg A.L., Keeney G.L., et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 2008; 108:619-26.
- Chen Y.L., Chang M.C., Huang C.Y., et al. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol 2012;6:360-69.
- Naumann R., Symanowski J., Ghamande S., et al. PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. J Clin Oncol 2010;28(suppl):abstr LBA5012b.ticity and premalignant changes. Lab Invest 1994;71(4):510-18.
- Apte S.M., Bucana C.D., Rillion J.J., et al. Expression of platelet-derived growth factor and activated receptor in clinical specimens if epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol Oncol 2004;93(1):78-86.
- Papapetropoulos A., Fulton D., Mahboubi K., et al. Angiopoetin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 2000;275(13):9102-105.
- Oliner J., Min H., Leal J., et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoetin-2. Cancer Cell 2004;6(5):507-16.
- Karlan B.Y., Oza A.M., Richardson G.E., et al. Randomized, double-blind, placebocontrolled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 2012;30:362-71.
- Kaye S.B., Lubinski J., Matulonis U., et al. Phase II, open-label, randomized, multicenter study of olaparib, a poly (ADP-ribose) polymerase ticity and premalignant changes. Lab Invest 1994;71(4):510-18.
Supplementary files
